Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;23(1):19-23.
doi: 10.1002/jcla.20280.

Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus

Carlos Geraldo Moura  1 , Isabella Lima, Lúcio Barbosa, Daniel Athanazio, Eliana Reis, Mitermayer Reis, Rufus W Burlingame, Mittermayer B Santiago
Affiliations

Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus

Carlos Geraldo Moura et al. J Clin Lab Anal. 2009.

Abstract

Background: Anti-C1q antibodies have been described in systemic lupus erythematosus (SLE) as well as in other connective tissue diseases. They have been considered as a marker for disease activity and presence of nephritis.

Objective: The aim of this study was to determine the prevalence of anti-C1q antibodies in Brazilian lupus patients as well as analyze their association with different clinical and serologic parameters.

Methods: Sera from 81 SLE patients, based on the American College of Rheumatology (ACR) criteria, were collected from a lupus referral outpatient clinic in Salvador, Brazil. Antibodies to C1q were detected by an enzyme-linked immunoassay (ELISA) kit and antibodies to other cellular antigens identified by indirect immunofluorescence on HEp-2 cell substrate (ANA), or Crithidia luciliae (dsDNA), and to nucleosome by ELISA. A cutoff of 20 U was established for anti-C1q and anti nucleosome assays.

Results: Anti-C1q antibodies were detected in 39.5% (32/81) of SLE sera. The presence of anti-C1q antibodies was associated with proteinuria (P=0.028) but not with other laboratory or clinical features, such as anti nucleosome or anti-dsDNA antibodies, hematuria, urinary casts or renal failure, leukopenia, pericarditis, pleuritis, malar rash, seizures, and psychosis. There was a positive correlation between the titers of anti-C1q antibodies and the systemic lupuis erythematosus disease activity index (SLEDAI) score (r=0.370; P=0.001).

Conclusion: This study in Brazilian SLE patients confirms previous findings of the association of anti-C1q antibodies with nephritis and disease activity.

PubMed Disclaimer

References

    1. Kallel‐Sellami M, Baili‐Klila L, Zerzeri Y, et al. Pediatric systemic lupus erythematosus with C1q deficiency. Ann N Y Acad Sci 2007;1108:193–196. - PubMed
    1. Trendelenburg M, Lopez‐Trascasa M, Potlukova E, et al. High prevalence of anti‐C1q antibodies in biopsy‐proven active lupus nephritis. Nephrol Dial Transplant 2006;21:3115–3121. - PubMed
    1. Mosca M, Chimenti D, Pratesi F, et al. Prevalence and clinico‐serological correlations of anti‐alpha‐enolase, anti‐C1q, and anti‐dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006;33:695–697. - PubMed
    1. Horak P, Hermanova Z, Zadrazil J, et al. C1q complement component and ‐antibodies reflect SLE activity and kidney involvement. Clin Rheumatol 2006;25:532–536. - PubMed
    1. Sinico RA, Radice A, Ikehata M, et al. Anti‐C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann N Y Acad Sci 2005;1050:193–200. - PubMed

Publication types